findings from the schizophrenia GWAS, further implicate dysregulated miR-137 as a potential contributor to schizophrenia pathology. In this work, we confirm the targeting of miR-137 to four genes significantly associated with schizophrenia, providing the first biological validation of a schizophrenia GWAS.
The dopamine stabilizers ACR16 and (À)-OSU6162 display nanomolar affinities at the s-1 receptor Converging in vivo evidence has advanced the s-1 receptor as a pharmacological target for the treatment of neurological and psychiatric disorders such as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia, schizophrenia, drug addiction and depression (see reviews refs 1,2). Considering their close structural resemblance to known s-1 receptor ligands, 3 we investigated the ability of dopaminergic stabilizers, a new class of phenylpiperidine compounds, to bind to s-1 receptors.
Dopaminergic stabilizers are presently being investigated for use in neurological and psychiatric disorders. 4, 5 These agents, which include (-)-OSU6162 and ACR16, have been shown to enhance locomotor activity in animals under conditions of low dopaminergic tone and to decrease activity when dopamine signaling is high, thus owing these drugs their name. 4 The compounds reduce locomotor activity in amphetamine-treated animals, which is indicative of antipsychotic activity and have also been shown to reduce social withdrawal in the ( þ )-MK-801 rat model of negative symptoms in schizophrenia. 6 Dopaminergic stabilizers have also shown clinical promise; the compound ACR16 (also known as pridopidine, or Huntexil) is currently in phase III clinical trials to treat Huntington's disease, 5 and another dopaminergic stabilizer has completed a phase I trial to evaluate its efficacy in reducing L-DOPA-induced dyskinesia (Identifier: NCT01023282). In addition, (À)-OSU6162 and ACR16 have shown antipsychotic activity in patients. 4 In line with the well-established involvement of dopamine signaling in movement and psychiatric disorders, investigations of 0 UTR sequence from predicted miR-137 targets were inserted. Each construct was co-transfected with miR-CNTL (black bars) or miR-137 (gray bars) and the ratio of Renilla/Firefly luciferase activity was normalized to miR-CNTL treatment. When miR-137 7-mer target site was deleted in reporter constructs (white bars), measured ratios were restored to that of the miR-CNTL treatment. Results are reported as the average of four replicates from two independent experiments þ s.e.m., *Po0.01 by two-way analysis of variance.
Letters to the Editor their molecular pharmacology have described dopaminergic stabilizers to act primarily at dopamine D 2 receptors, 4 where they display affinity in the micromolar range. 7 (À)-OSU6162 and ACR16 are reported to behave as neutral D 2 antagonists, 6, 8 or very weak partial agonists, 7 and display a rapid rate of dissociation from the D 2 receptor. 8 The latter characteristic was proposed to be central to their therapeutic action and favorable side-effect profile, 8 as well as their very low propensity for inducing catalepsy in animal models. 6 However, the ability of ACR16 to antagonize amphetamineinduced hyperactivity has also been reported to persist in D 2 receptor knock-out animals, 9 suggesting that additional targets might have a role in this action. Moreover, the mechanisms behind the pro-social effects of dopaminergic stabilizers in rat models of social withdrawal 6 remain unclear. Thus, in order to fully understand their putative anti-psychotic, anti-dyskinetic and procognitive effects, other targets beside dopamine receptors should be considered.
The s-1 receptor is a two-transmembrane domain protein that is widely expressed in the central nervous system. s-1 lacks homology to any known mammalian protein, is believed to function both as an endoplasmic reticulum chaperone and as a co-receptor for a variety of other transmembrane proteins and has been shown to modulate voltage-gated calcium-, potassium-and sodium channels, NMDA receptors and several G protein-coupled receptors.
1,2 Whereas the identity of its native ligand remains controversial, 1 the s-1 receptor has been demonstrated to bind cocaine, haloperidol, endogenous neurosteroids and the hallucinogenic trace amine, N,N-dimethyltryptamine. 10 Based on the actions of s-1 receptor ligands in both animal models and in patients, s-1 is currently being investigated as a pharmacological target for the treatment of neurological and psychiatric disorders such as L-DOPA-induced dyskinesia, schizophrenia (as adjuvant treatment addressing negative symptoms), drug addiction and depression. 1, 2 Compounds structurally related to dopaminergic stabilizers (Figure 1a) , for example, both enantiomers of 3-(3-hydroxyphenyl)-N-propylpiperidine (3-PPP), 3 have been shown to be high affinity s-1 ligands, raising the question whether some of the in vivo effects of dopaminergic stabilizers might in fact be mediated by s-1 receptors.
The present results reveal that the dopaminergic stabilizers, (À)-OSU6162 and ACR16, display nanomolar affinity for the human s-1 receptor heterologously expressed in HEK293 cells (Figure 1b ; Table 1 ), as well as in rat striatal membranes (Figure 1c ; Table 1 ). The affinity of ACR16 appears to be indistinguishable from that of the structurally related compound ( þ )-3-PPP; a ligand that has been widely used to study s-1 receptors. 3 Given that dopaminergic stabilizers have been described to act primarily via dopamine D 2 receptors, 4 two clinically used dopamine D 2 -like receptor agonists, (À)-apomorphine and bromocriptine, were tested and found to have only a low affinity for s-1 receptors in rat striatum (Figure 1c ; Table 1 ).
Dopaminergic stabilizers are a novel class of drug candidates that have shown clinical promise in the treatment of several severe neurological and neuropsychiatric disorders. Their mode of action is at present fragmentarily understood, but our data point to a previously overlooked aspect of their pharmacology. The present findings warrant further exploration of the relevance of s-1 receptor binding for the in vivo actions of dopaminergic stabilizers.
